Emitefur

Drug Profile

Emitefur

Alternative Names: BOF A2; Last-F

Latest Information Update: 20 Oct 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Otsuka Pharmaceutical
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Gastrointestinal cancer; Lung cancer; Non-small cell lung cancer; Pancreatic cancer

Most Recent Events

  • 15 Mar 2001 A phase I study has been added to the Cancer adverse events and pharmacokinetics sections
  • 28 Feb 2000 Preregistration for Breast cancer in Japan (PO)
  • 28 Feb 2000 Preregistration for Colorectal cancer in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top